【摘要】 目的探讨原发性肝癌肝动脉化疗栓塞术(transarterialchemoembolization,TACE)后重组人粒细胞集落刺激因子(rhG-CSF)适合的应用时间。方法入选对象均为细胞学或组织学确诊为原发性肝癌患者,随机分为两组试验组43例,在TACE后96h即开始皮下注射rhG-CSF;对照组42例,TACE后血常规WBC<4.0×109L-1时开始皮下注射rhG-CSF。结果试验组和对照组白细胞下降的最低值分别是(2.67±0.75)×109L-1和(2.17±0.76)×109L-1,t=3.053,P=0.003;白细胞低于4.0×109L-1的持续时间分别是(3.46±1.25)d和(4.35±1.42)d,t=3.069,P=0.003;Ⅲ～Ⅳ度中性粒细胞下降的发生率分别是20.9%和47.6%,χ2=6.73,P=0.009。每例患者rhG-CSF平均应用总量试验组和对照组分别是(850±107)μg和(885±103)μg,差异无统计学意义,t=1.536,P=0.125。结论肝癌TACE后96h开始应用rhG-CSF可减轻骨髓抑制的程度,为进行再次介入治疗提供保障。更多还原

【Abstract】 OBJECTIVE:To investigate the proper interval time of recombination human granulocyte colony stimulating factor ( rhG-CSF) after transcatheter arterial chemoembolization (TACE) in patients with primary liver carcinoma (PLC). METHODS: The total enrolled patients were diagnosed by histology or pathology. By using a randomized controlled trial, and 43 patients in a trial group were treated with rhG-CSF at 96 h of the ending of TACE, 42 patients in a control group were given rhG-CSF until WBC<4.0×109L -1 . RESUITS: The minimum value of the decreased white blood cell (WBC) in the trial group and control group 2.67±0.75×109L -1 and 2.17±0.76×109L -1 respectively (t=3.053, P=0.003), the number of days with WBC<4×109L -1 was 3.46±1.25 (days),4.35±1.42 (days) respectively (t=3.069, P=0.003 ), and the decreased incidence of the Ⅲ and Ⅳ degrees of absolute neutrophil count (ANC) was 20.9%, 47.6% respectively (χ2=6.73, P=0.009). The amount of rhG-CSF between the trial group and control group had no statistic difference. CONCLUSION: Administration of rhG-CSF at 96 h of the ending of TACE can relieve bone marrow depression, thereby ensuring TACE on the schedule time.更多还原